Wordt geladen...
Discontinuation of Imatinib Mesylate could Improve Renal Impairment in Chronic Myeloid Leukemia
We aim to report a CML case that had fluid retention and serum creatinine increase under long-term imatinib mesylate (IM) treatment. A 68-year-old woman was diagnosed with chronic myeloid leukemia, and IM was started in 2002 with a dose of 400 mg/day. She had achieved complete hematological, molecul...
Bewaard in:
| Gepubliceerd in: | Open Med (Wars) |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
De Gruyter
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6310919/ https://ncbi.nlm.nih.gov/pubmed/30613793 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1515/med-2019-0004 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|